Home / Health / DRC Ebola Strain Spurs Urgent Vaccine Development
DRC Ebola Strain Spurs Urgent Vaccine Development
4 Jun
Summary
- A new Ebola vaccine targets the Bundibugyo strain, not the Zaire strain.
- The outbreak has caused 61 deaths and 359 confirmed cases.
- Scientists are fast-tracking development using a COVID-19 vaccine platform.
Health workers in the Democratic Republic of Congo (DRC) are currently contending with an ongoing Ebola outbreak, while scientists globally are expediting the creation of a vaccine. The current outbreak is caused by the Bundibugyo strain of the virus, a different strain than the one targeted by existing approved vaccines, which are effective against the Zaire strain. This outbreak has resulted in 61 fatalities and 359 confirmed cases, impacting the DRC and neighboring Uganda.
The epicenter of this outbreak is in the Ituri province of northeastern DRC. This region faces significant challenges in containing the virus due to conflict, displacement of populations, a large migrant community, and under-resourced health facilities. Amidst these difficulties, researchers from the Oxford Vaccine Group at the University of Oxford are actively developing a vaccine candidate specifically for the Bundibugyo strain.
On June 1, 2026, three research groups, including the Oxford team, Moderna, and IAVI, received fast-track funding from the Coalition for Epidemic Preparedness Innovations. The Oxford group is adapting their ChADOx1 viral-vector platform, which was the foundation for the Oxford-AstraZeneca COVID-19 vaccine, for the Bundibugyo strain. This strategy allows them to concurrently conduct pre-clinical trials, animal testing, and manufacturing for human clinical trials, aiming for a phase one trial relatively soon.
Scientists acknowledge that creating an Ebola vaccine is possible, but the primary challenge lies in developing and distributing these vaccines effectively during non-outbreak periods to ensure readiness when and where they are needed.
